Evaluation of the Performance of Chembio's DPP(R) Syphilis Screen & Confirm Rapid Test System
Study Details
Study Description
Brief Summary
This study has been designed to evaluate the performance of the Chembio Diagnostics Systems, Inc. DPP® Syphilis Screen and Confirm rapid test. The device is intended to qualitatively and simultaneously detect the presence of antibodies to Non-treponemal and Treponema pallidum antigens in whole blood (capillary and venous), serum or plasma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Syphilis is a sexually transmitted disease (STD) caused by the spirochete Treponema pallidum. It is a chronic bacterial infection that remains a public health concern worldwide, especially in resource poor settings. Syphilis can be transmitted from infected women to their unborn children during pregnancy. Worldwide 12 million individuals are diagnosed with syphilis each year, 90% of them in developing countries. Diagnosed individuals are also at risk of becoming infected with and transmitting HIV [1].
Early and appropriate diagnosis and treatment prevents the transmission and development of severe complications. A rapid serologic test for specific antibodies to non-Treponemal and T. pallidum antigens is important in the early diagnosis and treatment monitoring of syphilis patients. In turn, this monitoring allows for the formulation of a more successful public health strategy. Various serologic tests are currently available such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR), fluorescent Treponemal antibody absorption (FTA-ABS) test, T. pallidum hemagglutination (TPHA) test, immunoenzymatic assay (EIA), Treponema pallidum particle agglutination (TPPA) test and Western blot (WB) test [2- 5]. The Chembio DPP Syphilis Screen & Confirm Assay is a unique non-Treponemal and Treponemal rapid point-of-care test, which is simple and easy to use. The DPP Syphilis Screen & Confirm Assay is a qualitative immunoassay for the detection of antibodies to the non-Treponemal and
- pallidum antigens in serum, plasma and whole blood.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Known Positive Syphilis Infection Individuals known to have a clinical diagnosis of Syphilis |
|
| High Risk for Syphilis Infection Individuals with previous and confirmed STD infection, MSM, persons with high risk sexual behavior or clinical examination with classic manifestations of syphilis. |
|
| Pregnant Women (High Risk and Low Risk) 1st or 3rd trimester from either High Risk (see description above) or Low Risk population. Low Risk are individuals not known to belong to any of the defined high-risk groups - i.e. "healthy patients" presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc… |
Outcome Measures
Primary Outcome Measures
- Clinical Performance Characteristics [12 months]
Support the claims that the DPP Syphilis Screen and Confirm test system is: substantially equivalent to a recognized laboratory method for syphilis presumptive screening tests, and substantially equivalent to a recognized laboratory method for syphilis confirmatory tests.
Secondary Outcome Measures
- Specimen Types [20 minutes]
The device detects specific antibodies to Non-Treponema and Treponema pallidum antigens in a variety of sample matrices: capillary whole blood, venous whole blood (with EDTA or heparin anticoagulant),serum and plasma (with EDTA or heparin anticoagulant).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Must be at least 13 years of age (no upper age limit).
-
Must be willing and able to receive post-test counseling, if applicable.
-
Must sign (and be given) a copy of the written Informed Consent form and or Assent form (if applicable).
-
Must be able to sustain fingersticks and venipuncture from the arm or hand only.
Exclusion Criteria:
-
Persons who are under 13 years of age
-
Persons who are unable to sustain venipuncture (as determined by investigator)
-
Have previously participated in this clinical trial
-
Persons who do not provide an informed consent, or withdraw consent.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mattel Childrens Hospital, University of California, David Geffen School of Medicine | Los Angeles | California | United States | 90095 |
| 2 | Therafirst Medical Center | Fort Lauderdale | Florida | United States | 33308 |
| 3 | University of Maryland | Baltimore | Maryland | United States | 21201 |
Sponsors and Collaborators
- Chembio Diagnostic Systems, Inc.
Investigators
- Principal Investigator: Neil T Constantine, Ph.D, University of Maryland School of Medicine
- Principal Investigator: Anthony LaMarca, M.D., Therafirst Medical Center
- Principal Investigator: Neva Yeganeh, M.D., University of California, Los Angeles, David Geffen School of Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CP-SYP-01